Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation

Author(s):  
Shuo Wang ◽  
Xiaoxue Lai ◽  
Cong Li ◽  
Meng Chen ◽  
Miao Hu ◽  
...  
Keyword(s):  
2012 ◽  
Vol 354 ◽  
pp. 21-31 ◽  
Author(s):  
Davide Bini ◽  
Maria Gregori ◽  
Ugo Cosentino ◽  
Giorgio Moro ◽  
Angeles Canales ◽  
...  

2021 ◽  
Vol 22 (22) ◽  
pp. 12338
Author(s):  
Jianrong Wu ◽  
Miaosen Wu ◽  
Hongtao Zhang ◽  
Xiaobei Zhan ◽  
Nian Wu

Oligomannuronic acid (MOS) from seaweed has antioxidant and anti-inflammatory activities. In this study, MOS was activated at the terminal to obtain three different graft complexes modified with sialic acid moiety (MOS-Sia). The results show that MOS-Sia addition can reduce the β-structure formation of Aβ42, and the binding effect of MOS-Sia3 is more obvious. MOS-Sia conjugates also have a better complexing effect with Ca2+ while reducing the formation of Aβ42 oligomers in solutions. MOS-Sia3 (25–50 μg/mL) can effectively inhibit the activation state of BV-2 cells stimulated by Aβ42, whereas a higher dose of MOS-Sia3 (>50 μg/mL) can inhibit the proliferation of BV-2 cells to a certain extent. A lower dose of MOS-Sia3 can also inhibit the expression of IL-1β, IL-6, TNF-α, and other proinflammatory factors in BV-2 cells induced by Aβ42 activation. In the future, the MOS-Sia3 conjugate can be used to treat Alzheimer’s disease.


2020 ◽  
Vol 8 (8) ◽  
pp. 2189-2201 ◽  
Author(s):  
Cong Li ◽  
Qiujun Qiu ◽  
Min Liu ◽  
Xinrong Liu ◽  
Ling Hu ◽  
...  

The application of SA-modified liposomes to target activated PBNs in the blood to improve the therapeutic efficiency of tumor treatment.


2000 ◽  
Vol 8 (8) ◽  
pp. 2027-2035 ◽  
Author(s):  
Yoshihiro Ikeuchi ◽  
Motoko Sumiya ◽  
Tetsuji Kawamoto ◽  
Naoshige Akimoto ◽  
Yuji Mikata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document